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ABSTRACT
Objective the clinical benefit of ursodeoxycholic acid 
(UDca) in primary biliary cholangitis (PBc) has never 
been reported in absolute measures. the aim of this 
study was to assess the number needed to treat (nnt) 
with UDca to prevent liver transplantation (lt) or death 
among patients with PBc.
Methods the nnt was calculated based on the 
untreated lt- free survival and Hr of UDca with respect 
to lt or death as derived from inverse probability of 
treatment weighting- adjusted cox proportional hazard 
analyses within the global PBc Study group database.
Results We included 3902 patients with a median 
follow- up of 7.8 (4.1–12.1) years. the overall Hr of 
UDca was 0.46 (95% ci 0.40 to 0.52) and the 5- year 
lt- free survival without UDca was 81% (95% ci 79 to 
82). the nnt to prevent one lt or death within 5 years 
(nnt5y) was 11 (95% ci 9 to 13). although the Hr of 
UDca was similar for patients with and without cirrhosis 
(0.33 vs 0.31), the nnt5y was 4 (95% ci 3 to 5) and 20 
(95% ci 14 to 34), respectively. among patients with 
low alkaline phosphatase (alP) (≤2× the upper limit of 
normal (Uln)), intermediate alP (2–4× Uln) and high 
alP (>4× Uln), the nnt5y to prevent one lt or death 
was 26 (95% ci 15 to 70), 11 (95% ci 8 to 17) and 5 
(95% ci 4 to 8), respectively.
Conclusion the absolute clinical efficacy of UDca with 
respect to lt or death varied with baseline prognostic 
characteristics, but was high throughout. these findings 
strongly emphasise the incentive to promptly initiate 
UDca treatment in all patients with PBc and may 
improve patient compliance.
InTROduCTIOn
Primary biliary cholangitis (PBC) is a chronic 
disease of the liver characterised by destruction of 
the small intrahepatic bile ducts and formation of 
hepatic fibrosis.1 2 It was recently estimated that 
nowadays 40% of patients with PBC will develop 
cirrhosis within 10 years, at which point patients 
are at increased risk of liver failure and hepatocel-
lular carcinoma.3 As a result, the overall survival 
of patients with PBC is substantially impaired 
as compared with that of a matched general 
population.4
The choleretic and hydrophilic bile acid ursode-
oxycholic acid (UDCA) is currently considered as 
the standard of care for patients with PBC.5–7 Based 
on long- term clinical experience, UDCA is consid-
ered to have a favourable safety profile. The strong 
association between UDCA therapy and prolonged 
liver transplantation (LT)- free survival was recently 
Significance of this study
What is already known on this subject?
 ► Ursodeoxycholic acid is a safe drug that is 
recommended for the treatment of patients 
with primary biliary cholangitis (PBC).
 ► Ursodeoxycholic acid treatment has been 
associated with a reduced relative risk of liver 
transplantation or death.
 ► Up to 30% of patients with PBC is currently 
not being treated with ursodeoxycholic acid in 
Western cohorts.
What are the new findings?
 ► Although the relative risk reduction related to 
ursodeoxycholic acid treatment with respect to 
liver transplantation or death is relatively stable 
over patients’ baseline characteristics, the 
absolute clinical efficacy varies but is generally 
high.
 ► The clinical efficacy of ursodeoxycholic acid can 
be estimated individually according to patients’ 
GLOBE score.
How might it impact on clinical practice in the 
foreseeable future?
 ► Based on these findings, physicians should 
initiate treatment with ursodeoxycholic acid in 
all patients suffering from PBC.
 ► Patients may be more willing to start treatment 
and remain compliant based on their 
individually calculated clinical efficacy measure.
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substantiated in both a large American cohort and our own 
international cohort, with a dose–response relationship high-
lighting the importance of the 13–15 mg/kg dose recommen-
dation.8 Still, even in recent Western cohorts, as much as 30% 
of patients remained untreated and suboptimal UDCA dosages 
were frequently used.9 10 More awareness of and attention for 
the clinical efficacy of UDCA are thus needed in order to opti-
mise the medical management and clinical outcome of the popu-
lation with PBC.
While previous studies only assessed the relative reduction of 
the risk of clinical outcomes with UDCA therapy, our under-
standing of the impact of UDCA could benefit from reports of 
absolute measures of clinical efficacy. The number needed to 
treat (NNT) to prevent one clinical event represents such an 
absolute clinical efficacy measure with clear interpretation for 
physicians, patients and policymakers. Currently, it is not known 
how many patients with PBC should be treated with UDCA to 
prevent one LT or death. Although previously we showed that 
the relative risk reduction with UDCA is stable over various 
patient characteristics, the absolute risk reduction may not be.8 
In this study we aimed to assess the NNT with UDCA to prevent 
one LT or death among patients with PBC. The secondary aims 
were to evaluate the NNT in various subgroups of patients with 
PBC and to estimate the NNT for the individual patient with 
PBC.
PATIenTS And MeTHOdS
Study population and design
For the current study we used the data of patients included in 
the database of the Global PBC Study Group, which is an inter-
national collaboration between liver units across eight countries 
in Europe and Northern America. The database contains data 
from representative long- term followed cohorts on an individual 
patient level of both UDCA- treated and untreated patients. All 
patients had an established diagnosis of PBC according to inter-
nationally accepted guidelines.6 7 Patients were only included 
in case of sufficient follow- up (>6 months and ≥2 recorded 
visits) and when dates of starting UDCA treatment and/or clin-
ical events were known. For the current analyses we excluded 
patients in case an autoimmune overlap syndrome, based on the 
Paris criteria,11 or other concomitant liver disease was present. 
Further details on the methodology of data collection have been 
described in further detail elsewhere.8 12 In line with our previous 
work, 3902 patients were included for the current analyses.8
Statistical analysis
The outcome measure of the current study was the combined 
endpoint of LT and all- cause mortality. Baseline was considered 
to be the first centre visit in untreated patients and the start of 
treatment in patients receiving UDCA. Treatment with UDCA 
for PBC is recommended lifelong and usually initiated promptly 
after diagnosis. Patients were followed until LT or death. In 
patients who remained alive without LT, the follow- up was 
censored at their last visit to the centre. Patients were considered 
lost to follow- up when it was unclear whether they were either 
alive, deceased or underwent LT at the time of data collection. 
Missing baseline data were assumed to be missing at random 
and were handled by means of multiple imputation (SAS Proc 
MI, Markov Chain Monte Carlo method). Hereto, 10 databases 
were generated with use of Rubin’s rules to estimate the parame-
ters and the SE. The biochemical values included for imputation 
were alkaline phosphatase (ALP), aspartate aminotransferase, 
alanine aminotransferase (ALT), total bilirubin, albumin and 
platelet count. Categorical or binary variables were not imputed.
Because treatment was not assigned randomly in our study 
population, our analyses were performed following inverse prob-
ability treatment weighting (IPTW).13 Hereto, following stabili-
sation, weights were assigned to each individual patient based on 
the predictive values derived from a logistic regression model, 
including baseline patient characteristics and laboratory parame-
ters (age, gender, calendar year of diagnosis, total bilirubin, ALP, 
ALT, platelet count, albumin), with UDCA therapy as dependent 
variable.8 14 After weighting a balance assessment was performed 
which previously showed that there were no remaining differ-
ences in baseline characteristics between the UDCA- treated and 
untreated patients.15 Subsequently, the association between time 
to LT or death and UDCA therapy was assessed through Cox 
proportional hazard regression analyses.
The NNT to prevent one LT or death within (t) years with 
UDCA therapy can be calculated with the observed LT- free 
survival in patients without treatment and the estimated benefit 
of UDCA on LT- free survival, which are both derived from 
IPTW- adjusted Cox regression analyses. The NNTs were esti-
mated using the following formula: NNT=(1/(LT- free surviv-
aluntreated(t)
HR UDCA) − (LT- free survivaluntreated(t))).
16 The 95% CI 
of both the LT- free survival and the HR of UDCA was taken 
into account to address the uncertainty of the NNT. Unrounded 
numbers of HR and untreated survival were used to calculate the 
NNT. The NNT was always rounded up. Although the NNT to 
prevent one LT or death can be calculated for every time point 
(t) during the follow- up (NNT(t)y), we primarily report the NNT 
to prevent one LT or death within 5 years (NNT5y) throughout 
the manuscript. Stratified analyses were performed based on 
categorised baseline characteristics.
The individualised NNT5y was estimated using the GLOBE 
score, a validated objective prognostic tool which accurately 
predicts LT- free survival after 1 year of UDCA therapy. The 
GLOBE score is calculated with the following formula: 0.044378 
× age + 0.93982 × LN(bilirubin) + 0.335648 × LN(ALP) 
+ 2.266708 × albumin + 0.002581 × platelets (per 109/L) 
+ 1.216865 (bilirubin and ALP in ‘× upper limit of normal’ 
and albumin in ‘× lower limit of normal’).17 First, the predic-
tive accuracy of the GLOBE score (calculated with the variables 
at baseline) for LT or death was assessed in untreated patients 
using the c- statistic.18 19 Calibration analyses were performed by 
comparing the predicted mortality rates with those observed, 
stratified for four range categories of the GLOBE score. Second, 
a multivariable Cox regression model for LT or death including 
the GLOBE was constructed. Linearity was assessed by including 
polynomial terms, which remained included in the multivariate 
model in case these were statistically significantly associated 
with the outcome measure. Subsequently, the HR of UDCA was 
calculated for each value of the GLOBE score. With the GLOBE 
score thus representing an untreated LT- survival estimate and an 
HR of UDCA, the NNT could be predicted for the individual 
patient.
The clinical efficacy of UDCA treatment was also assessed 
according to biochemical response at year 1. Hereto, patients 
were stratified based on their ALP level, with a cut- off of 1.67× 
the upper limit of normal (ULN). An ALP ≥1.67× ULN was 
defined as a suboptimal response. Cox proportional hazard 
analyses provided HRs regarding LT or death of UDCA per 
response group and were adjusted for all baseline characteristics 
as these are associated with both the long- term outcome and the 
biochemical response to UDCA. The untreated LT- free survival 
was estimated based on the median GLOBE score at baseline, 
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Table 1 Baseline characteristics
Overall
n=3902
udCA- treated
n=3529
untreated
n=373 P value
Age at diagnosis, years* 52.3 (11.9) 52.1 (11.7) 54.1 (13.4) <0.001
Female, n (%) 3552/3902 (91.0) 3209/3529 (90.9) 343/373 (92.0) 0.510
AMA- positive, n (%) 3507/3862 (90.8) 3175/3491 (90.9) 332/371 (89.5) 0.418
Year of diagnosis† 1996 (1990–2003) 1997 (1990–2003) 1992 (1982–2000) <0.001
Histological disease stage, n (%)‡ <0.001
  Stage I 784/2173 (36.1) 739/2076 (35.6) 45/97 (46.4)
  Stage II 671/2173 (30.9) 657/2076 (31.6) 14/97 (14.4)
  Stage III 365/2173 (16.8) 351/2076 (16.9) 14/97 (14.4)
  Stage IV 353/2173 (16.2) 329/2076 (15.8) 24/97 (24.7)
Serum bilirubin (ULN)† 0.63 (0.44–1.00) 0.62 (0.44–1.00) 0.65 (0.43–1.38) 0.081
Serum ALP (ULN)† 2.29 (1.41–3.95) 2.32 (1.46–4.00) 1.94 (1.11–3.51) <0.001
Serum AST (ULN)† 1.53 (1.03–2.31) 1.56 (1.05–2.34) 1.25 (0.75–2.00) <0.001
Serum ALT (ULN)† 1.68 (1.05–2.63) 1.71 (1.09–2.68) 1.20 (0.75–1.83) <0.001
Serum albumin (LLN)† 1.15 (1.06–1.25) 1.15 (1.06–1.25) 1.15 (1.03–1.26) 0.840
Platelet count (x 109/L)† 245 (190–300) 248 (195–303) 217 (146–271) <0.001
Biochemical disease stage, n (%)§ <0.001
  Early 1576/2296 (68.6) 1376/1980 (69.5) 200/316 (63.3)
  Advanced 559/2296 (24.3) 484/1980 (24.4) 75/316 (23.7)
  Severe 161/2296 (7.0) 120/1980 (6.1) 41/316 (13.0)
Serum bilirubin was missing for 1020 (26%) patients, serum ALP for 1069 (27%), serum AST for 1175 (30%), serum ALT for 1294 (33%), serum albumin for 1533 (39%) and 
platelet count for 1720 (44%). AMA status was missing for 40 (1.9%) patients.
*Data are expressed as mean and SD.
†Data are expressed as median and IQR.
‡Histological disease stage according to Ludwig and Scheuer’s classification.28
§Biochemical disease stage according to Rotterdam criteria.29
ALP, alkaline phosphatase; ALT, alanine aminotransferase;AMA, antimitochondrial antibodies; AST, aspartate aminotransferase; LLN, lower limit of normal; UDCA, ursodeoxycholic 
acid; ULN, upper limit of normal.
thus prior to initiation of UDCA therapy, in each response 
group.
All statistical tests were two- sided, and a p value <0.05 was 
considered to be statistically significant. The significance level 
for interactions was set at p<0.01 to correct for multiple testing. 
Statistical analyses were performed in SPSS Statistics V.21.0 and 
SAS V.9.4.
Patient and public involvement statement
Patients were not involved in the design or conduct of this study.
ReSulTS
Cohort characteristics
Included in the study were 3902 patients with PBC, predomi-
nantly female (91.0%) and with a mean (SD) age of 54.3 (11.9). 
Treated with UDCA were 3529 (90.4%) patients and not treated 
with UDCA were 373 (9.6%) patients. In our study the median 
(IQR) interval between the first centre visit and start of UDCA 
was 2.9 months (0–29). Table 1 shows the baseline characteristics 
according to the treatment with UDCA prior to IPTW. Following 
adjustment with IPTW there were no remaining baseline char-
acteristics which differed statistically significantly between the 
two groups. Patients were followed for a median of 7.8 (IQR 
4.1–12.1) years. Of a total of 3902 patients, 306 patients (7.8%) 
were lost to follow- up. During follow- up, a total of 299 patients 
underwent LT and 567 patients died. The primary endpoint of 
LT or death was observed in 721 UDCA- treated patients and 
145 untreated patients.
nnT5y with udCA to prevent one lT or death
Following IPTW adjustment, the 5- year cumulative LT- free 
survival without UDCA therapy was 81.0% (95% CI 79.3 to 
82.7). The overall adjusted HR of UDCA for LT or death was 
0.46 (95% CI 0.40 to 0.52, p<0.001). As a result, the NNT5y to 
prevent LT or death in one patient was 11 (95% CI 9 to 13). With 
a proportional HR of UDCA over time, the cumulative LT- free 
survival in untreated patients at (t) years drives the estimated 
NNT to prevent one LT or death over that specific duration of 
therapy. With a 10- year cumulative LT- free survival of 60.7% 
(95% CI 58.2 to 63.4) in the absence of UDCA, the NNT10y to 
prevent one LT or death was 6 (95% CI 5 to 7). Figure 1 shows 
the NNT(t)y to prevent one LT or death according to various 
durations of UDCA therapy.
Relative risk reduction versus absolute risk reduction in 
stratified subgroups
Table 2 presents the adjusted HRs of UDCA with respect to LT 
or death, the adjusted cumulative LT- free survival in UDCA- 
untreated patients and the adjusted NNT to prevent one LT or 
death within 5 and 10 years for various subgroups of patients. 
As previously described, the HR of UDCA for LT or death was 
stable over the baseline characteristics and only differed statis-
tically significantly among patients stratified according to their 
baseline age and ALP and albumin levels.8
As example, when comparing the relative reduction of the risk 
of LT or death with UDCA therapy between patients with early 
biochemical disease (adjusted HR 0.37, 95% CI 0.30 to 0.47) 
or patients with intermediate biochemical disease (adjusted 
HR 0.32, 95% CI 0.25 to 0.40) with patients with advanced 
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Figure 1 Adjusted NNT to prevent one LT or death according to 
treatment duration. The solid line represents the adjusted NNT with 
UDCA among patients with PBC to prevent one LT or death according 
to various treatment durations on the x- axis. The dotted lines represent 
the 95% CI, which are based on both the 95% CI of the adjusted HR of 
UDCA with respect to the occurrence of LT or death and 95% CI of the 
cumulative LT- free survival in patients without UDCA therapy. Results 
are adjusted for sex, age, year of diagnosis, albumin, platelet count, 
bilirubin, alkaline phosphatase, aspartate aminotransferase and alanine 
aminotransferase. LT, liver transplantation; NNT, number needed to treat; 
PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.
biochemical disease (adjusted HR 0.50, 95% CI 0.37 to 0.70), 
a small but not significant difference is observed. In absolute 
terms, however, the adjusted NNT5y to prevent one LT or death 
was substantially higher among those with early biochemical 
disease (22, 95% CI 17 to 32) as opposed to those with interme-
diate or advanced disease (5 (95% CI 4 to 6) and 5 (95% CI 3 to 
8), respectively). The beneficial NNT in patients with advanced 
biochemical response is explained by the higher 5- year cumu-
lative incidence of LT or death (26.2%, 95% CI 20.4 to 33.7).
The IPTW- adjusted HR of UDCA was statistically significantly 
stronger among the youngest quartile of patients (≤46.0 years; 
0.33, 95% CI 0.24 to 0.46) as compared with those in the inter-
quartile age range (46.0–62.7 years; 0.46, 95% CI 0.37 to 0.56) 
and the oldest quartile of patients (>62.7 years; 0.60, 95% CI 
0.48 to 0.76), while the cumulative 5- year LT- free survival rates 
without UDCA were rather similar among the three age groups. 
The stronger adjusted HR of UDCA among patients ≤46 years 
resulted in an adjusted NNT5y to prevent one LT or death of 9 
(95% CI 7 to 14), which was lower as compared with 10 (95% 
CI 8 to 14) in those aged 46.0–62.7 years and 14 (95% CI 9 to 
28) in those older than 62.7 years.
Predicted individual nnT to prevent one lT or death
In the untreated population, the discriminative ability of the 
GLOBE score was strong with a c- statistic of 0.81 (95% CI 0.78 
to 0.85). The observed 5- year transplant- free survival was in line 
with the predicted estimates using the GLOBE score (figure 2). 
Figure 3 shows the polynomial function of the HR of UDCA 
according to the GLOBE score, which was significant to the 
fourth degree. Using the estimated 5- year survival that relates 
to every value of the GLOBE score, we predicted the NNT5y for 
any given GLOBE score (figure 4). An NNT5y ≤10 to prevent 
one LT/death is achieved in patients with a GLOBE score ≥0.94 
(NNT10y=5), an NNT5y of 20 in patients with a GLOBE score of 
0.10 (NNT10y=9), while the NNT5y is ≥50 in case the GLOBE 
score is <−0.62 (NNT10y=20).
Relative risk reduction versus absolute risk reduction 
according to biochemical response
In our cohort, 2084 (59.1%) UDCA- treated patients had an 
ALP <1.67× ULN at year 1, and their 5- year and 10- year 
LT- free survival rates were 94.0% and 84.7%. These patients 
had a lower risk of LT or death (adjusted HR 0.35, 95% CI 
0.29 to 0.42, p<0.0001) as opposed to those without UDCA. 
In contrast, 1445 (40.9%) patients had a suboptimal biochem-
ical response. In these patients the 5- year and 10- year LT- free 
survival rates were 88.0% and 70.9%. Although less strong, a 
suboptimal response to UDCA remained associated with a statis-
tically significantly lower risk of LT or death as compared with 
no UDCA (adjusted HR 0.42, 95% CI 0.36 to 0.50, p<0.0001).
Among patients with an ALP <1.67× ULN, the median 
GLOBE score prior to UDCA treatment was −0.0266, which 
translates into an estimated 5- year and 10- year LT- free survival 
rates of 94.0% and 84.7%. As a result, the NNT was 26 (95% CI 
24 to 29) and 11 (95% CI 10 to 12) to prevent one LT or death 
in 5 or 10 years, respectively. In contrast, the median GLOBE 
score prior to UDCA treatment was 0.6978 among patients with 
a suboptimal biochemical response, leading to estimated 5- year 
and 10- year LT- free survival rates of 88.0% and 70.9%. As a 
result, their NNT5y was 15 (95% CI 14 to 18) and the NNT10y 
was 7 (95% CI 6 to 8).
dISCuSSIOn
In our large international cohort, the overall number of patients 
with PBC which needed to be treated with UDCA to prevent 
one LT or death within 5 years was 11, as the related relative risk 
reduction was 2.2 and the cumulative 5- year incidence of LT/
death in untreated patients was approximately 19%. This NNT, 
as an absolute measure of clinical efficacy, further decreased in 
case one LT/death had to be prevented over longer periods of 
time. This is relevant, as UDCA is recommended as a lifelong 
therapy for patients with PBC. The NNT fluctuated according 
to baseline patient characteristics, which is predominantly 
explained by differences in the natural history of PBC in various 
subgroups. Nevertheless, the clinical efficacy of UDCA in terms 
of the NNT to postpone one LT or death with at least 5 years can 
be considered low throughout.
In the current study, the NNT was assessed across all relevant 
patient subgroups. We previously found that the relative reduc-
tion in the risk of LT/death associated with UDCA was gener-
ally stable.8 For instance, the HR of UDCA was similar among 
patients with cirrhosis (HR 0.33) and patients without cirrhosis 
(HR 0.31). However, the absolute clinical efficacy of UDCA was 
considerably lower among patients with cirrhosis (NNT5y=4) as 
compared with those without cirrhosis (NNT5y=20). This differ-
ence is explained by the substantially higher cumulative 5- year 
incidence of LT/death in untreated patients with cirrhosis (52%) 
than in those without cirrhosis (7%). This emphasises the rele-
vance of appreciating the clinical setting when evaluating the 
clinical benefit of a therapeutic intervention, which is consid-
ered when using the NNT as a measure of efficacy. The relative 
risk reduction associated with UDCA with respect to LT/death 
did differ according to ALP, age and albumin.8 ALP is an estab-
lished prognostic marker for long- term outcome.12 20 Among 
patients with a high ALP level (>4× ULN), the HR of UDCA 
was stronger and the cumulative 5- year incidence of LT/death in 
the absence of treatment was higher in comparison with patients 
with lower ALP levels. Both factors contributed to the consider-
ably lower NNT5y to prevent LT/death in patients with high ALP 
(5) than in those with low ALP levels (≤2× ULN: 26) before the 
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Table 2 NNT with UDCA to prevent one LT or death in 5 and 10 years in subgroups of patients with PBC
Characteristics
Adjusted HR 
(95% CI)* P value HR
untreated lT- free 
survival5y (95% CI) nnT5y (95% CI)†¶
untreated lT- free 
survival10y (95% CI)
nnT10y 
(95% CI)†¶
Sex
  Male 0.52 (0.35 to 0.77) 0.0011 0.68 (0.60 to 0.76) 8 (5 to 21) 0.55 (0.46 to 0.64) 6 (4 to 15)
  Female 0.44 (0.38 to 0.52) <0.0001 0.82 (0.80 to 0.84) 11 (9 to 14) 0.62 (0.59 to 0.64) 6 (5 to 7)
Age (years)
  ≤46.0 0.33 (0.24 to 0.46) <0.0001 0.83 (0.79 to 0.86) 9 (7 to 14) 0.60 (0.55 to 0.66) 5 (3 to 6)
  46.0–62.7 0.46 (0.37 to 0.56) <0.0001 0.80 (0.78 to 0.83) 10 (8 to 14) 0.67 (0.64 to 0.71) 7 (5 to 9)
  >62.7 0.60 (0.48 to 0.76) <0.0001 0.81 (0.77 to 0.84) 14 (9 to 28) 0.52 (0.47 to 0.58) 7 (5 to 13)
Cirrhosis‡
  No 0.32 (0.24 to 0.42) <0.0001 0.92 (0.90 to 0.95) 20 (14 to 34) 0.71 (0.66 to 0.76) 6 (5 to 8)
  Yes 0.31 (0.24 to 0.40) <0.0001 0.48 (0.42 to 0.54) 4 (3 to 5) 0.33 (0.27 to 0.39) 3 (3 to 4)
Disease stage§
  Early 0.37 (0.30 to 0.47) <0.0001 0.92 (0.91 to 0.94) 22 (17 to 32) 0.78 (0.75 to 0.80) 8 (6 to 11)
  Intermediate 0.32 (0.25 to 0.40) <0.0001 0.62 (0.57 to 0.67) 5 (4 to 6) 0.22 (0.17 to 0.28) 3 (3 to 4)
  Advanced 0.50 (0.37 to 0.70) 0.0001 0.26 (0.20 to 0.34) 5 (3 to 8) 0.14 (0.92 to 0.20) 5 (4 to 9)
ALP
  ≤2× ULN 0.61 (0.45 to 0.82) 0.0014 0.90 (0.87 to 0.92) 26 (15 to 70) 0.79 (0.75 to 0.82) 13 (8 to 35)
  2–4× ULN 0.46 (0.36 to 0.59) <0.0001 0.82 (0.79 to 0.85) 11 (8 to 17) 0.59 (0.56 to 0.64) 6 (4 to 8)
  >4× ULN 0.36 (0.25 to 0.52) <0.0001 0.66 (0.62 to 0.70) 5 (4 to 8) 0.41 (0.36 to 0.46) 4 (3 to 5)
Bilirubin
  ≤ULN 0.39 (0.32 to 0.48) <0.0001 0.91 (0.90 to 0.92) 19 (15 to 27) 0.75 (0.72 to 0.78) 7 (6 to 10)
  >ULN 0.40 (0.33 to 0.48) <0.0001 0.49 (0.45 to 0.53) 4 (4 to 5) 0.20 (0.16 to 0.25) 4 (3 to 4)
Albumin
  <LLN 0.32 (0.24 to 0.43) <0.0001 0.35 (0.29 to 0.41) 3 (3 to 4) 0.15 (0.11 to 0.21) 3 (3 to 4)
  ≥LLN 0.46 (0.40 to 0.54) <0.0001 0.87 (0.86 to 0.89) 16 (13 to 21) 0.68 (0.66 to 0.71) 7 (6 to 9)
Platelet count
  <150×109/L 0.48 (0.35 to 0.46) 0.0007 0.52 (0.47 to 0.58) 5 (4 to 9) 0.27 (0.22 to 0.34) 4 (3 to 7)
  ≥150×109/L 0.44 (0.37 to 0.52) <0.0001 0.86 (0.84 to 0.87) 14 (11 to 18) 0.68 (0.65 to 0.70) 7 (5 to 8)
*HRs were adjusted for sex, age, year of diagnosis, albumin, platelet count, bilirubin, alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase;.
†The 95% CI of the NNT was based on both the 95% CI of the adjusted HR of UDCA as well as on the 95% CI of the cumulative 5- year LT- free survival in patients without UDCA 
therapy.
‡Baseline histological data were available for 2173 patients;.
§Biochemical disease stage according to Rotterdam criteria.29
¶As the number needed to treat always needs to be rounded up, decimal differences in absolute clinical efficacy cannot be presented.
ALP, alkaline phosphatase; LLN, lower limit of normal; LT, liver transplantation; NNT, number needed to treat; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid; ULN, 
upper limit of normal; 5y, 5 years; 10y, 10 years.
initiation of UDCA. Young age was associated with a stronger 
relative risk reduction related to UDCA treatment. Although 
younger age is normally inversely associated with the risk of 
death, patients who develop PBC at a young age are known to 
have a more aggressive phenotype.21 Indeed, the cumulative 
LT- free survival among untreated patients with PBC aged ≤46 
years in our cohort was similar as compared with that of older 
patient subgroups. As a result, the NNT5y was only slightly lower 
in patients ≤46 years (9) as compared with patients aged 46–63 
years (10) and >63 (14). In line with the above, the absolute 
clinical efficacy of UDCA therapy was stronger among patients 
with a suboptimal biochemical response at year 1, despite an 
inferior relative risk reduction. Although this might seem coun-
terintuitive, this is explained by the impaired untreated LT- free 
survival in these patients when compared with those with an 
ALP <1.67× ULN after year 1.
As exemplified in the previous paragraph, the untreated prog-
nosis strongly affects the absolute clinical efficacy of UDCA. 
For an individual patient, multiple baseline characteristics 
need to be considered, while it would be desirable to estimate 
a single patient- specific NNT. We showed that the GLOBE 
score, originally developed as an objective tool to estimate 
LT- free survival after 1 year on UDCA treatment, also accurately 
predicts prognosis in untreated patients. Hereafter, we esti-
mated the individualised clinical efficacy of UDCA according 
to the GLOBE score. In this analysis we allowed the HR of 
UDCA to fluctuate with the GLOBE score as it incorporates ALP 
and age, the two variables with most profound and significant 
impact on the relative risk reduction of UDCA. An estimation 
of an individual NNT can be helpful for patient counselling 
and supporting therapeutic compliance. For example, patients 
might be more willing to accept perceived side effects due to an 
improved understanding of the expected absolute risk reduction. 
Noteworthy is that a high NNT with UDCA was usually a result 
of a favourable natural history rather than the absence of a rela-
tive benefit of UDCA.
To the best of our knowledge, this is the first study to assess the 
benefit of UDCA treatment in PBC in absolute risk reduction as 
measured by the NNT to prevent clinical endpoints. Assessment 
of the NNT is rare in the field of hepatology, but has recently 
gained popularity in many other fields of medicine. The advan-
tage of the NNT is that it is easy to interpret for both patients 
and physicians as it combines the therapy- induced relative risk 
reduction and patients’ a priori risk of unfavourable outcome 
in a single parameter. The NNT can be expressed for any given 
treatment duration, which is especially relevant for chronic 
 o
n
 June 9, 2020 at Barnes Library M
edical School. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319057 on 16 December 2019. Downloaded from 
6 Harms MH, et al. Gut 2019;0:1–8. doi:10.1136/gutjnl-2019-319057
Hepatology
Figure 2 Observed versus predicted LT- free survival according to 
categorised risk groups. The dots represent four subgroups of patients 
in our cohort based on GLOBE score range with the corresponding 
mean predicted LT- free survival (x- axis) and observed LT- free survival 
(y- axis). From left to right: (1) a GLOBE score of >0.91, corresponding to 
a 5- year risk of >20%; (2) a GLOBE score of 0.51–0.91, corresponding 
to a 5- year risk of 10%–20%; (3) a GLOBE score of −0.21 to 0.51, 
corresponding to a 5- year risk of 5%–10%; and (4) a GLOBE score 
≤−0.21, corresponding to a 5- year risk of ≤5%. LT, liver transplantation.
Figure 3 HR of UDCA on LT- free survival according to the GLOBE 
score. The graph shows a non- linear relationship, in which the function 
of the GLOBE score was significant to the fourth degree. LT, liver 
transplantation; UDCA, ursodeoxycholic acid.
Figure 4 Individualised NNT5y according to the GLOBE score, 
visualised against the estimated 5- year risk of LT or death. The solid 
line represents the estimated 5- year risk of LT or death according to the 
GLOBE score, plotted against the right y- axis. The dotted line represents 
NNT for 5 years to prevent the occurrence of one LT or death according 
to the GLOBE score, plotted against the left y- axis. The grey bars 
represent an independent histogram of the number of patients in our 
cohort according to their GLOBE score, in which the number of patients 
represented by the bars is shown on the left y- axis. 5yr, 5 years; LT, liver 
transplantation; NNT, number needed to treat.
diseases such as PBC in which lifelong treatment is required. 
While policymakers may be interested in long- term effects of 
therapy, patients are more likely to prioritise short- term bene-
fits. Moreover, physicians’ willingness to treat is reported 
to be dependent of the measure in which treatment benefit is 
presented. Providing information on both relative and absolute 
clinical efficacy may therefore prevent misinterpretation and aid 
well- informed decision making in daily clinical practice.22–24
As part of our study we validated the GLOBE score to accu-
rately predict the LT- free survival in untreated patients with 
PBC. The availability of such an objective natural history score 
is relevant, also in light of novel second- line therapies which 
will no longer be compared with a placebo arm given the strong 
evidence for a beneficial effect of UDCA for all patients with 
PBC.8 The GLOBE score can thus aid to evaluate the potential 
additional benefit of new drugs that are added to the treat-
ment with UDCA, and might be preferable over older predic-
tion models such as the Mayo Risk Score as it is solely based on 
readily available and objective parameters.25
Strengths of the current study include the use of a large, inter-
nationally representative cohort with long- term follow- up and 
many clinical endpoints in both UDCA- treated and untreated 
patients. Furthermore, to ensure accurate estimation of the 
NNT, both the 95% CI of the HR of UDCA as well as the CI of 
the estimated survival in the untreated population were taken 
into account. Additionally, in a sensitivity analysis in patients 
diagnosed in or after 1990, performed to ensure results are 
compatible with present- day clinical practice, the relative risk 
reduction associated with UDCA therapy was similar (data not 
shown). A number of limitations should also be noted. First, a 
potential selection bias in this study is represented by the fact 
that the majority of included patients were treated in tertiary 
liver centres. Second, potential improvement in survival within 
the timespan that is chosen to express the NNT is not consid-
ered when using the NNT as a measure of risk reduction, which 
could thus lead to an underestimation of treatment benefit. 
Third, the NNT assumes a causal relationship between UDCA 
and prolonged LT- free survival. This has long been subject to 
debate, especially due to Cochrane reporting an absence of treat-
ment benefit.26 As this is a retrospective study in which IPTW 
was used to adjust for the small differences in baseline charac-
teristics, residual confounding can never be fully ruled out. We 
are lacking data on the reasons for not treating patients with 
PBC with UDCA, but especially shortly after its introduction it 
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can be hypothesised that physicians may have been unaware of 
UDCA or not convinced about its benefits. Also, patients may 
have been unwilling to use this relatively new drug at that time. 
Because UDCA has no relevant contraindications, however, we 
consider it to be unlikely that the association between UDCA and 
improved LT- free survival is completely confounded by a patient- 
related factor which would have influenced both the chance of 
receiving UDCA and the risk of LT or death. In fact, both the 
positive association with clinical outcome in extensively adjusted 
analyses in large cohort studies and the finding of an improved 
LT- free survival in UDCA- treated patients with advanced disease 
in an older randomised controlled trial have provided a general 
consensus on the assumed causal UDCA treatment benefit.6–8 27
In conclusion, in this first study to assess the efficacy of UDCA 
in absolute measures, we report that the NNT with UDCA to 
prevent LT or death is generally low, but can be assessed for indi-
vidual patients with PBC. These results provide a clear under-
standing of the clinical importance of optimised UDCA therapy 
for patients and doctors, thereby stimulating compliance and 
treatment uptake.
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